Should we anticoagulate after bioprosthetic aortic valve replacement?

References

• Brown JM, O’Brien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J. Thorac. Cardiovasc. Surg. 137(1), 82–90 (2009).
   PubMed Web of Science ®Google Scholar
• McClure RS, Narayanasamy N, Wiegerinck E et al. Late outcomes for aortic valve replacement with carpentier-edwards pericardial bioprosthesis: up to 17-Year Follow-Up in 1,000 Patients. Ann. Thorac. Surg. 89(5), 1410–1416 (2010).
   PubMedGoogle Scholar
• Dellgren G, David TE, Raanani E, Armgstrong S, Ivanov J, Rakowski. Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. J. Thorac. Cardiovasc. Surg. 124, 146–154 (2002).
   PubMedGoogle Scholar
• Ruel M, Chan V, Bédard P et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults <60 years of age. Circulation 116(11 Suppl.), I294–I300 (2007).
   PubMedGoogle Scholar
• Ruel M, Kulik A, Rubens F, Bedard P, Masters R, Pipe A, Mesana T. Late incidence and determinants of reoperation in patients with prosthetic heart valves. Eur J Cardiothorac Surg. 25(3), 364–370 (2004).
   PubMedGoogle Scholar
• Chan V, Kulik A, Tran A et al. Long-term clinical and hemodynamic performance of the Hancock II versus the Perimount aortic bioprostheses. Circulation 122(11 Suppl.), S10–S16 (2010).
   PubMedGoogle Scholar
• Neville PH, Aupart MR, Diemont FF, Sirinelli AL, Lemoine EM, Marchand MA. Carpentier-Edwards pericardial bioprosthesis in aortic or mitral position: a 12-year experience. Ann. Thorac. Surg. 66( Suppl. 66), S143–S147 (1998).
   PubMedGoogle Scholar
• Frater RW, Salomon NW, Rainer WG, Cosgrove DM, Wickman E. The Carpentier-Edwards pericardial aortic valve: intermediate results. Ann. Thorac. Surg. 53, 764–771 (1992).
   PubMed Web of Science ®Google Scholar
• Cosgrove DM, Lytle BW, Williams GW. Hemodynamic performance of the Carpentier-Edwards pericardial valve in the aortic position in vivo. Circulation 72( Suppl. 72), II146–II152 (1985).
   PubMedGoogle Scholar
• Bonow RO, Carabello B, de Leon AC Jr et al. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 32, 1486–1582 (1998).
   PubMed Web of Science ®Google Scholar
• Golke-Barwolf C, Acar J, Oakley C, et al. Guidelines for prevention of thromboembolic events in valvular heart disease. Eur. Heart. J. 16, 1320–1330 (1995).
   PubMedGoogle Scholar
• Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves: Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 119(Suppl.), 220s–227s (2001).
   PubMedGoogle Scholar
• Jamieson WR, Cartier CP, Allard M. Surgical management of valvular heart disease. Can. J. Cardiol. 20(Suppl. E) 15 (2004).
   Google Scholar
• Heras M, Chesebro JH, Fuster V, et al. High Risk of Thromboemboli Early After Bioprosthetic Cardiac Valve Replacement. J. Am. Coll. Cardiol. 25, 1111–1119 (1995).
   PubMed Web of Science ®Google Scholar
• Stein B, Fuster V, Halperin JL. Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. Circulation 80(6), 1501–1513 (1989).
   PubMedGoogle Scholar
• McClung JA, Stein JH, Ambrose JA, Herman MV, Reed GE. Prosthetic heart valves: a review. Prog. Cardiovasc. Dis. 26(3), 237–2370 (1983).
   PubMedGoogle Scholar
• Baglin TP, Rose PE, Walker ID, et al. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. Br. J. Haematol. 101, 374–387 (1998).
   PubMedGoogle Scholar
• Bonow RO, Carabello BA, Chatterjee K et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am. Coll. Cardiol. 52(13), e1–e142 (2008).
   PubMed Web of Science ®Google Scholar
• Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based C linical Practice Guidelines. Chest 141(2 Suppl.), e576S–600S (2012).
   PubMedGoogle Scholar
• Vahanian A, Alfieri O, Andreotti F. Guidelines on the management of valvular heart disease (version 2012). Eur. Heart J. 33, 2451–2496 (2012).
   PubMed Web of Science ®Google Scholar
• Vaughan P, Waterworth PD. An audit of anticoagulation practice among UK Cardiothoracic Consultant surgeons following valve replacement/repair. J Heart Valv Dis. 14, 576–582 (2005).
   PubMedGoogle Scholar
• Colli A, Verhoye JP, Heijmen R, et al. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur. J. Cardiothorac. Surg. 33, 531–6 (2008).
   PubMedGoogle Scholar
• Anderson JM, Schoen EJ. Interaction of blood with artificial surfaces. In: Thrombosis, Embolism and Bleeding. Butchart E, Bodnar E ( Eds.). ICR Publishers, London, UK, 160–171 (1992).
   Google Scholar
• Piper C, Hering D, Horstkotte D. Prosthetic valve thrombosis: predisposition and diagnosis. Eur. Heart J. 22(Suppl.), Q16–Q21 (2001).
   PubMedGoogle Scholar
• Horstkotte D, Aul C, Seipel L et al. Influence of valve type and valve function on chronic intravascular hemolysis following mitral and aortic valve replacement using alloprostheses. Z. Kardiol. 72, 119–31 (1983).
   PubMedGoogle Scholar
• Pitcher I, Curry P. Emboli from a prosthetic heart valve during postmenopausal oestrogen therapy. BMJ 2, 244–5 (1979).
   PubMedGoogle Scholar
• Staffurth JS, Gibberd MC, Fui SNG. Arterial embolism in thyrotoxicosis with atrial fibrillation. BMJ. 2, 688–90 (1977).
   PubMedGoogle Scholar
• Butchart EG. Prosthesis-specific and patient-specific anticoagulation. In: Thrombosis, Embolism and Bleeding. Butchart EG, Bodnar E ( Eds.).. ICR Publishers, London, 293–317 (1992).
   Google Scholar
• Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 258, 1183–6 (1987).
   PubMed Web of Science ®Google Scholar
• Butchart EG, Moreno de la Santa P, Rooney SJ, et al. Arterial risk factors and cerebrovascular events following aortic valve replacement. J. Heart Valve Dis. 4, 1–8 (1995).
   PubMedGoogle Scholar
• Butchart EG, Ionescu A, Payne N, Giddings J, Grunkemeier GL, Fraser AG. A new scoring system to determine thromboembolic risk after heart valve replacement. Circulation 108( Suppl. 108), II68–II74 (2003).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Guntensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1(8597), 1242–1245 (1988).
   PubMed Web of Science ®Google Scholar
• Orszulak TA, Schaff HV, Mullany CJ, et al. Risk of Thromboembolism With the Aortic Carpentier-Edwards B ioprosthesis. Ann. Thorac. Surg. 59, 462–468 (1995).
   PubMed Web of Science ®Google Scholar
• Blair KL, Hatton AC, White WD et al. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. Circulation 90 (5 Pt 2), II214–II219 (1994).
   PubMedGoogle Scholar
• Moinuddeen K, Quin J, Shaw R et al. Anticoagulation is unnecessary after biological aortic valve replacement. Circulation 98(19 Suppl.), II95–II98 (1998).
   PubMedGoogle Scholar
• Sundt TM, Zehr KJ, Dearani JA et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J. Thorac. Cardiovasc. Surg. 129, 1024–1031 (2005).
   PubMed Web of Science ®Google Scholar
• El Bardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J. Thorac. Cardiovasc. Surg. 139(5), 1137–1145 (2010).
   PubMedGoogle Scholar
• Gherli T, Colli A, Fragnito C, et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 110, 496–500 (2004).
   PubMed Web of Science ®Google Scholar
• Aramendi JI, Mestres CA, Matrinez-Leon J, Campos V, Munoz G, Navas C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (TRAC): prospective, randomized, co-operative trial. Eur. J. Cardiothorac. Sur. 27, 854–860 (2005).
   PubMedGoogle Scholar
• Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to apirin (woa) after aortic valve replacement with the st. jude medical epicTM heart valve bioprosthesis: results of the woa epic pilot trial. J. Heart Valve Dis. 16(6), 667–671 (2007).
   PubMed Web of Science ®Google Scholar
• Brueck M, Kramer W, Vogt P et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur. J. Cardio-thorac. Sur. 32, 108–112 (2007).
   PubMedGoogle Scholar
• Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 308(20), 2118–2125 (2012).
   PubMed Web of Science ®Google Scholar
• Brennan JM, Edwards FH, Zhao Y, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J. Am. Coll. Cardiol. 60(11), 971–977 (2012).
   PubMed Web of Science ®Google Scholar
• Toeg H, Bjerre LM, Ruel M. Letter to editor: warfarin discontinuation and outcomes after bioprosthetic aortic valve replacement. JAMA 309(12), 1225 (2013).
   PubMedGoogle Scholar
• Rodriguez RA, Rubens F, Rodriguez CD, Nathan HJ. Sources of variability in the detection of cerebral emboli with transcranial Doppler during Cardiac Surgery. J. Neuroimaging 16, 126–132 (2006).
   PubMedGoogle Scholar
• Rodriguez RA, Williams KA, Babaev A, Rubens F, Nathan HJ. Effect of perfusionist technique on cerebral embolization during cardiopulmonary bypass. Perfusion 20, 3–10 (2005).
   PubMedGoogle Scholar
• Al-Atassi T, Lam K, Forgie M et al. Cerebral microembolization after bioprosthetic aortic valve replacement: comparison of warfarin plus aspirin versus aspirin alone. Circulation 126(11 Suppl. 1), S239–S244 (2012).
   PubMedGoogle Scholar